Bing

SEARCH HISTORY

Still, no sign of new chemical entity (NCE) status by FDA; no partnership or buyout has materialized; and the stock is hovering near pre-clinical trial result levels. However, before being too short-sided, let's quickly review some of AMRN's strengths from ...
Seeking Alpha · 3/6/2013
Amarin Co. plc (NASDAQ:AMRN)‘s stock had its “hold” rating reissued by Zacks in a research note issued on Thursday. Zacks’ analyst wrote, “Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical …
wkrb13.com · 4/30/2015
NEW YORK (TheStreet) -- Amarin (AMRN) shares are falling, down 8.5% to $1.39 on Thursday, following the announcement that the company, along its wholly owned subsidiary, Corsicanto Limited, have entered into an senior note exchange agreement with …
The Street · 5/15/2014
More from Bing News
BEDMINSTER, N.J., and DUBLIN, Ireland, Oct 16, 2013 (GLOBE NEWSWIRE via COMTEX) -- Amarin Corporation plc AMRN, -3.98% a biopharmaceutical company focused on the commercialization and development of therapeutics to improve …
Market Watch · 10/16/2013
and AMRN stock 52-week range is between $0.78 and $3.33 per share Avago Technologies Limited (Nasdaq:AVGO) delivered better-than-expected quarterly profit in its financial results and said that it will acquire fellow chipmaker Broadcom Corporation ...
Galaxy Stocks · 5/28/2015
Amarin Corporation plc (Nasdaq: AMRN) announced that the number of patients enrolled in the company's REDUCE-IT cardiovascular outcomes study of Vascepa (icosapent ethyl) capsules has surpassed 6,000. The REDUCE-IT (Reduction of …
StreetInsider · 9/25/2013
AuRico Gold Inc. (AUQ) of the Basic Materials sector is down -0.56% (change from open -0.28%) this morning trading at a volume of 206,130 shares and price of $3.52. AuRico Gold Inc. (AUQ)’s weekly performance is 3.51% and compared to their 52 …
wallstreetscope.com · 4/24/2015
Well, as we know there are two types of person in the stock market one is trader and another ... We told our members in facebook private group to buy Amarin Corporation plc (ADR)(NASDAQ:AMRN) on April 28th at $2.07. Now look at the price of the stock ...
Market News Call · 5/28/2015
Amarin (NASDAQ:AMRN) is one of today's worst performing low-priced stocks, down 6.0% to $2.18 on 1.6x average daily volume. Thus far today, Amarin has traded 3.0 million shares, vs. average volume of 1.9 million shares per day. The stock has …
Financial News Network Online · ByRobert Cotter · 5/29/2015
Small-cap biopharma Amarin Corp. (NASDAQ: AMRN) finally caught a break yesterday in its ongoing ... Given that investors flooded into this stock following this ruling, let's consider if now is indeed the time to buy this beaten-down biopharma.
The Motley Fool · 5/29/2015

Amarin Corporation

Company
Amarin Corporation is a biopharmaceutical company headquartered in Bedminster, New Jersey. The company develops and markets me…
Amarin Corporation is a biopharmaceutical company headquartered in Bedminster, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. Amarin develops the drug Vascepa which is a prescription grade omega-3 fatty acid. In December 2007, the company acquired Ester Neurosciences Limited for 8.1 million USD. Amarin CEO Joe Zakrzewski has said that the company would like to first work on building its infrastructure out to commercialize the drug in the United States. Recently on July 26, 2012, their lead-candidate drug named Vascepa received FDA-approval. Vascepa will also be a key competitor against GlaxoSmithKline's Lovaza.
Data from: Wikipedia